Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimer's disease model mice

Journal of Nuclear Medicine

Volumn 57, Issue 2, 2016, Pages 291-296

  Shukuri, Miho ^a,b   Mawatari, Aya ^a   Ohno, Masahiro ^a   Suzuki, Masaaki ^c   Doi, Hisashi ^a   Watanabe, Yasuyoshi ^a   Onoe, Hirotaka ^a  

^a RIKEN   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Animal imaging; Cyclooxygenase; Microglia; neuroinflammation; Molecular imaging; PET

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CARBON 11; CYCLOOXYGENASE 1; KETOPROFEN METHYL ESTER C 11; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; CARBON; KETOPROFEN; MEMBRANE PROTEIN; PTGS1 PROTEIN, MOUSE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; ENANTIOMER; FRONTAL CORTEX; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MICROGLIA; MOUSE; MOUSE MODEL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ENCEPHALITIS; ENZYMOLOGY; GENETICS; HUMAN; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; PREFRONTAL CORTEX; PROCEDURES; SCINTISCANNING; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; CARBON RADIOISOTOPES; CYCLOOXYGENASE 1; DISEASE PROGRESSION; ENCEPHALITIS; HIPPOCAMPUS; HUMANS; KETOPROFEN; MACROPHAGE ACTIVATION; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 84958640830     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166116     Document Type: Article

References (30)

1. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083-1088.
2. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharideinduced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:8843-8853.
3. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7:161-167.
4. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70:1672-1677.
5. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl). 2001;101:2-8.
6. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol. 1999;58:1135-1146.
7. 11C-labeling of 2-arylpropionic acids and their esters: construction of a PET tracer library for a study of biological events involved in COXs expression. Chemistry. 2010;16:4250-4258.
8. 11C-ketoprofen methyl ester. J Nucl Med. 2011;52:1094-1101.
9. Ghezzi P, Melillo G, Meazza C, et al. Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. J Pharmacol Exp Ther. 1998;287:969-974.
10. Guide for the Care and Use of Laboratory Animals. Washington, DC: Government Printing Office; 1985. NIH publication 86-23.
11. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
12. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1:345-347.
13. Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD. Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol. 2014;88:565-572.
14. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem. 1996;271:33157-33160.
15. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA. 1994;91:5252-5256.
16. Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23:8-21.
17. Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62: 66-71.
18. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
19. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters b-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci. 2003;23:7504-7509.
20. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639-647.
21. de Vries EF. Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation. Curr Pharm Des. 2006;12:3847-3856.
22. Laube M, Kniess T, Pietzsch J. Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity: a critical update. Molecules. 2013;18:6311-6355.
23. Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 2008;22:1491-1501.
24. Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY). 2009;1:234-244.
25. Choi SH, Aid S, Caracciolo L, et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem. 2013;124:59-68.
26. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des. 2008;14:1419-1427.
27. Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. J Neuroinflammation. 2014;11:120-131.
28. Hommet C, Mondon K, Camus V, et al. Neuroinflammation and b amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. Dement Geriatr Cogn Disord. 2014;37:1-18.
29. Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz). 2012;60:251-266.
30. Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. January 20, 2015 [Epub ahead of print].